AbstractBySubCategory

Colorectal Cancer

Gastrointestinal (Colorectal) Cancer

2013 ASCO Annual Meeting

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.
Prognosis factors and colorectal cancer survival at Oncologos del Occidente from Colombia, South America. J. A. Chacon Cardona

e14692

General epidemiologic colorectal cancer profile in Oncologos del Occidente from Colombia, South America. T. Sanchez Villegas

e14693

Disparities between young and elderly patients in the first course of treatment for stage II and III rectal cancers. Y. Tilahun

e14546

Expression of transcription factor Scratch2 in colorectal cancer. K. Ivanov

e14669

Phase II study of weekly scheduled irinotecan and capecitabine treatment in advanced colorectal cancer patients. W. Li

e14644

Pooled survival analysis of series using the liver-first approach to the management of colorectal cancer with synchronous liver-limited metastases demonstrates wide variation in outcome. S. Jegatheeswaran

e14547

Prospective analysis of UGT1A1 genotyping for predicting toxicities in advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens: Interim safety analysis of a Japanese observational study. W. Ichikawa

3535

Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database. D. W. Sommeijer

3520

Neoadjuvant chemoradiotherapy (NACRT) in patients with locally advanced rectal cancer (RC): Results of a phase I/II trial in Japan. T. Koyama

e14670

Is oxaliplatin a good partner for EGFR monoclonal antibodies as first-line treatment in KRAS wild-type metastatic colorectal cancer? A meta-analysis. F. Wen

e14645

Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy. I. Yildiz

e14594

Comparing KRAS mutation testing by pyrosequencing versus allele specific primary extension methods in colorectal cancer specimens. K. R. Sampat

e14522

Improving QOL and safety while reducing costs: Evidence-based adjuvant chemotherapy of colorectal cancer (CRC). W. S. Shimp

e14646

EGFR and KRAS mutations during anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer: Clinically relevant? L. Karayan-Tapon

3513

Sporadic rectal cancers in young adults: Experience from a tertiary cancer center in India. M. Malik

e14694

Inmunohistochemical expression of thymidilate synthase, ERCC1, pKDR, and LDH5 as predcitive markers of efficacy in patients with advanced colon cancer treated with XELOX or FOLFOX with or without bevacizumab. J. Garde

e14671

Prognostic factors of recurrence of colorectal cancers with microsatellite instability after curative resection: An AGEO retrospective multicenter study. D. Tougeron

3536

Treatment outcome according to tumor ERCC1 expression status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. C. Bokemeyer

3537

Predictive significance of VEGF and HIF-1α expression in metastatic colorectal cancer patients receiving chemotherapy combined with bevacizumab. V. Berk

e14672

Use of VEGF expression to predict for first-line treatment chemotherapy regimen in metastatic colorectal cancer. M. Ozkan

e14695

Can PET CT predict response in locally advanced rectal cancer patients treated with induction FOLFOX? S. Gunduz

e14696

Time-dependent estimates of recurrence and survival in colon cancer: clinical decision support system tool development for adjuvant therapy and oncological outcome assessment. S. Steele

e14500

Association between smoking and tumor grade in colorectal cancer: A retrospective analysis from a single institution. R. Elsoueidi

e14673

Cetuximab and chemotherapy in the treatment of patients with initially “nonresectable” colorectal (CRC) liver metastases: Long-term follow-up of the CELIM trial. G. Folprecht

3538

A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study. N. S. Azad

3539

Using quantitative sensory testing as an early predictor of chronic oxaliplatin neuropathy in gastrointestinal cancer patients. S. M. Reddy

3540

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). V. Heinemann

LBA3506

Beyond VEGF inhibition: Comparative efficacy analysis of novel VEGF and non-VEGF therapeutic agents in phase I trials for patients with metastatic colorectal cancer (mCRC). S. R. Patel

3541

Retrospective analysis of dose intensity, toxicity, and clinical outcomes in 5-fluorouracil based regimens in the treatment of metastatic colorectal cancer. K. E. Mulder

e14595

Chemotherapy-induced diarrhea in older patients with colorectal cancer receiving fluoropyrimidines: A retrospective review. L. H. Iyer

e14647

Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC). A. Cheng

e14501

5FU/LV with or without irinotecan in patients with resected stage II-III rectal cancer: Final analysis of R98 intergroup study. C. Delbaldo

3542

Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial. S. Kasper

e14502

Phase II trial of target-guided personalized chemotherapy in first-line metastatic colorectal. A. Cubillo

3543

Use of RAS pathway activation or KRAS mutation status to predict cetuximab response in CRC patient-derived xenografts. H. Li

3544

Comparison of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in patients with colorectal carcinoma for a predictive marker for tumor recurrence. H. Sakihama

e14548

Comprehensive pharmacogenetic profiling of advanced colorectal cancer. A. Madi

3509

Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases. J. Xu

e14523

The "real life" impact of adding bevacizumab to first-line treatment of metastatic colorectal cancer: A retrospective large database study. A. Hammerman

e14571

Effect of 3-5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: FACS randomized controlled trial. D. Mant

3500

Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC). J. Taïeb

3525^

ALK and ROS1 gene rearrangements detected in colorectal cancer (CRC) by fluorescence in situ hybridization (FISH). A. J. Weickhardt

3545

Stereotactic body radiotherapy response and local control rates for hepatic oligometastases. B. Goodman

3546

Effect of oxaliplatin-containing neoadjuvant chemotherapy on tumor volume in locally advanced rectal cancer and sensitivity of surviving tumor cells to radiotherapy. K. Flatmark

3547

Cochrane systematic review and meta-analysis of adjuvant chemotherapy for stage II colon cancer. B. M. Meyers

3548

The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer. K. I. Abdul Jalil

3549

Worse prognosis of KRAS C.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with first-line triplet chemotherapy plus bevacizumab (FIr-B/FOx) and post-progression. G. Bruera

e14596

Ovarian metastases in colorectal carcinoma. I. Yucel

e14697

A multicenter dose-finding study of irinotecan (CPT-11) based on UGT1A1 polymorphisms for metastatic colorectal cancer. H. Sato

e14572

Safety and feasibility of yttrium-90 (Y-90) treatment for primary and metastatic liver tumors at a community hospital. B. K. Martinez

e14698

Molecular characteristics and prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX. D. Lee

3550

Impact of K-ras status on FOLFOX and XELOX regimens efficacy in metastatic colorectal (mCRC) patients (pts). M. Fedyanin

e14674

Functional polymorphism in the microRNA-367 binding site as a prognostic factor for colonic cancer. Y. Chae

e14549

Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC). R. Dienstmann

3551

Novel data processing and image co-registration algorithm for region-specific lipid profiling in colorectal cancer tissue using DESI imaging mass spectrometry. R. Mirnezami

e14620

Phase II trial of cetuximab (Cmab) plus irinotecan (CPT-11) for chemorefractory Japanese patients with advanced and/or metastatic colorectal cancer (mCRC), to evaluate the efficacy and safety based on KRAS, BRAF, PIK3CA, NRAS, and AKT1 mutation status (T-CORE0801). H. Shimodaira

e14597

Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer. W. Van Criekinge

3552

Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147. A. Lee

3510

Genetic variations in miRNA binding site of TPST1 and ZG16B associated with prognosis for patients with colorectal cancer. B. Kang

3553

Regular statin users and colorectal cancer (CRC) prognosis. W. Ma

3554

Noninferiority of S-1 to UFT/LV as adjuvant chemotherapy for stage III colon cancer: A randomized phase III trial (ACTS-CC). Y. Nakamoto

3518

Palliative chemotherapy in advanced colorectal cancer patients age 80 or older. P. Lai

e14598

Randomized controlled trials (RCTs) examining continuous (CS) versus intermittent strategies (IS) of delivering systemic treatment (Tx) for untreated metastatic colorectal cancer (mCRC): A meta-analysis from the Cancer Care Ontario program in evidence-based care. S. R. Berry

3534

Survival benefit associated with the number of chemotherapy/biologic treatment lines in 5,129 elderly metastatic colon cancer patients. N. Hanna

e14524

Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC). R. B. Corcoran

3507

CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer. M. van Engeland

e14503

Clinical impact of histologic subtypes and somatic mutations in peritoneal carcinomatosis from colorectal cancer. F. Bibeau

e14621

Colorectal cancer gene expression profiling using nanostring nCounter analysis. K. K. Ciombor

3555

Neoadjuvant pelvic perfusion may facilitate resection of pelvic recurrent rectal cancer. H. J. Wanebo

e14599

FOCUS4: A prospective molecularly stratified, adaptive multicenter program of randomized controlled trials for patients with colorectal cancer (CRC). K. Shiu

TPS3645

Incidence and risk of hand foot skin reaction (HFSR) in patients receiving regorafenib for cancer: A meta-analysis. V. Belum

e14713

Intensive CT scan surveillance for patients who have undergone curative intent treatment for colorectal cancer: The Medstar Washington Hospital Center experience. K. Leventakos

e14675

Neoadjuvant chemoradiotherapy (NCRT) using concurrent S-1 and irinotecan in rectal cancer: Impact on long-term clinical outcomes and prognostic factors. A. Tsutsui

3556

Tolerability of raltitrexed when it is used in monotherapy and in combination with oxaliplatin (TOMOX) as advanced colorectal cancer treatment in normal clinical practice. M. Constenla

e14648

Accuracy of Wif1 methylated gene test and microbial changes identifying colorectal cancer. I. Sobhani

e14525

MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC): Phase I, first-in-human study in patients (pts) with advanced gastrointestinal (GI) malignancies expressing GCC. K. Almhanna

TPS3646

The role of AP-1 in colon cancer stem cells. M. Chatziioannou

e14699

Quality of life in a multicenter phase II trial of metastasectomy for intra- and extra-hepatic metastases from colorectal adenocarcinoma. A. C. Wei

e14573

BRAF and KRAS mutations as additional risk factors in the context of clinical parameters of patients with colorectal cancer. V. C. Popovici

3522

Hsa-mir-31-3p effects on gene expression in colorectal cancer cell lines and patients. R. Thiébaut

e14600

Phase II study of first-line combined chemotherapy bevacizumab with modified RPMI regimen for elderly or frail patients with unresectable or metastatic colorectal cancer (OGSG0802) update analysis. T. Satoh

e14601

Comparison of efficacy and toxicity of bevacizumab in combination with chemotherapy in the first, second, and third or higher line of treatment for metastatic colorectal carcinoma (mCRC): Data from the Czech multi-institutional registry. I. Kiss

e14622

Risk for developing brain metastases from colorectal cancer in long-term survivors with lung metastases and KRAS mutations. F. Zoratto

e14574

Genes involved in EGFR-degradation to predict for efficacy in metastatic colorectal cancer patients treated with cetuximab. S. Stintzing

3557

FOLFIRI plus bevacizumab (bev) as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) who have failed first-line bev plus oxaliplatin-based therapy: The randomized phase III EAGLE study. H. Tamagawa

3516

Survival after resection plus intra-operative radiofrequency ablation (IRFA) to treat colorectal liver metastases (CLM): Results of an international collaborative study. S. Evrard

3558

Analysis of totally implantable venous access port systems (TIVAPS) related adverse events (AEs) in metastatic colorectal cancer (mCRC) patients treated with and without bevacizumab. T. Tsushima

e14623

Association between c-Met expression and tumor recurrence in colorectal cancer patients after liver resection. H. Shoji

3559

Preoperative radiotherapy (preop RT) in rectal cancer: Impact of chemotherapy on the outcome—Long-term results of the randomized 22,921 phase III trial of EORTC. J. Bosset

3560

Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study. J. Flejou

3524

Treatment patterns in metastatic colorectal cancer (mCRC) in Slovakia. T. Salek

e14700

A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. J. N. Primrose

3504

Efficacy and toxicity of second-line AIO plus irinotecan (IRI) after pretreatment with AIO plus oxaliplatin (L-OHP) in the sequential therapy of metastatic colorectal cancer (CRC). A. Wein

3561

Hsa-miR-31-3p expression in FFPE tumor samples as a predictor of anti-EGFR response in patients with metastatic colorectal cancer. G. Manceau

3562

Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors. S. Pant

3564

Tumor-related and treatment-related colostomy-free survival (CFS) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU/CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA): Results of ACT II. R. Glynne-Jones

3532

Use of biologics in addition to chemotherapy in the treatment of elderly Medicare patients with stage IV metastatic colon cancer. C. D. Mullins

e14602

Severe falls among older adults with resected stage II/III colon cancer receiving chemotherapy. N. K. LoConte

e14550

EGFL7 polymorphism to predict tumor response in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI and bevacizumab (BV). J. E. Li

3565

Use of genetic variants in pericyte-driven tumor vessel maturation genes to predict treatment efficacy in mCRC patients treated with FOLFIRI/bevacizumab. N. B. Volz

3566

Use of genetic variants in immune response genes to predict clinical outcome in mCRC patients treated with cetuximab-based therapy. A. M. Schultheis

3567

Use of genetic variants in wnt signaling pathway to predict gender and tumor location dependent survival in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI and bevacizumab (BEV). Y. Ning

3568

Adjuvant chemotherapy (AC) outcomes in young (YP) and elderly patients (EP) with high-risk stage II colon cancer (CC). A. Kumar

3569

Retrospective analysis of dose intensity, toxicity, and clinical outcomes in 5-fluorouracil (5FU)-based regimens in adjuvant treatment of colon cancer. J. Loree

e14575

Global clinical experience with adjuvant oxaliplatin/5-fluorouracil (5-FU)-based chemotherapy for colon cancer: Outcomes of the ACCElox registry. Y. Park

e14624

A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT). A. R. Townsend

e14506

Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) in patients with locally advanced rectal cancer after preoperative chemoradiotherapy followed by surgery: A randomized phase II study (The ADORE). Y. Hong

3570

A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer: The SOFT study. D. Takahari

3519

Pharmacodynamic effects of regorafenib in metastatic colorectal carcinoma (mCRC). A. L. Wong

e14507

Tumor perivascular PDGFBR as an independent prognostic factor in metastatic colorectal cancer. M. B. Lindh

3571

Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer. M. K. Boisen

3572

Six years of experience in citoreductive surgery and the application of HIPEC-oxaliplatin. S. Nikolic

e14676

On-treatment progression-free survival analysis of ziv-aflibercept/FOLFIRI treatment within 28 days of end of treatment in metastatic colorectal cancer: Updated efficacy results from the VELOUR study. D. Ferry

3573

Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and ziv-aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment. P. Ruff

3574

Survival outcomes in U.S. patients with metastatic colorectal cancer: A retrospective database analysis. K. B. Knopf

e14576

Prognostic impact of KRAS and BRAFV600E mutations stratified by tumor site in resected stage III colon cancer patients treated with adjuvant mFOLFOX6 with or without cetuximab: NCCTG N0147 (Alliance). F. A. Sinicrope

3523

North American (NA) subgroup results from VELOUR: Ziv-aflibercept versus placebo plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen. E. P. Mitchell

e14528

Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC). T. Pinter

3575

Detection of the BRAFV600E protein in human colon carcinomas by a mutation-specific antibody. T. C. Smyrk

3576

Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. F. Marmorino

e14577

A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy. C. Eng

3508

Survival benefits of adjuvant chemotherapy in high-grade stage II and III colon cancer. W. Tsang

e14529

Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study. C. L. Loprinzi

3501

Thymidylate synthase (TS) expression as a prognostic molecular marker in stage II/III colon cancer. D. Klingbiel

3577

Lung and colon cancer costs among chemotherapy patients after an FDA policy change. K. Stroupe

e14578

Risk of second primary cancers after treatment for locoregional rectal cancer. C. S. Nangia

3578

Capecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal cancer. V. H. Lee

e14530

Influence of sex and anthropometric factors on tumor biologic characteristics of colorectal cancer: A cohort study. J. Brandstedt

3579

FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC). L. Salvatore

e14531

Survival benefit and complications of primary tumor resection (PTR) in patients with stage IV colorectal cancer (CRC) in the era of modern chemotherapy: A systematic review and meta-analysis. S. Ahmed

3580

Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database. Q. Shi

3533

Phase II study of dacarbazine for metastatic colorectal cancer: Final results with MGMT analysis. A. Amatu

3581

Secondary resection in a general mCRC population with cetuximab-based first-line treatment: Interim analysis of the German noninterventional study ERBITAG. U. P. Neumann

e14532

Causes of urban-rural disparities in adjuvant chemotherapy (AC) for rectal cancer (RC). K. Rasool Javaheri

e14603

Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. N. Turan

e14533

Impact of nodal metastasis on survival of stage IV colon cancer: Analysis of National Cancer Data Base (NCDB). M. Shaik

3582

Use of tumor size to predict long-term survival in colon cancer patients: Analysis of National Cancer Data Base (NCDB). S. Saha

3583

Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. S. Y. Brule

3528

Primary tumor resection in metastatic colorectal cancer (mCRC): A prospective cohort study. S. Wong

3584

The efficacy and safety of XELOX plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer: Final report of CCOG-0902 study. N. Hayashi

e14552

The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies. S. Yuki

e14604

Multimodality treatment combining chemotherapy, liver surgery, peritoneal resection and hyperthermic intraperitoneal chemotherapy (HIPEC) for metastatic colorectal cancer (mCRC) patients with synchronous liver metastases (LM) and peritoneal carcinomatosis (PC): A multicenter study of the French Association of Surgery. R. Lo Dico

e14534

Final results of the AIO 0307 study: A controlled, randomized, double-blind phase II study of FOLFOX6 or FOLFIRI combined with sorafenib (S) versus placebo (P) in second-line metastatic colorectal carcinoma (mCRC) treatment. T. Hoehler

3586

Evaluation of treatment benefit to an unselected population of patients with metastatic colorectal cancer, referred to oncological treatment. S. E. Nielsen

e14677

A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). C. M. Booth

TPS3647

Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III noninferiority trial (SAKK 41/06). D. Koeberle

3503

The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC). H. S. Hochster

3587

Peripheral blood monocytes as biomarkers for colorectal cancer. H. Prenen

3588

Dachshund 2 protein, a novel neuroendocrine marker associated with favorable tumor characteristics and clinical outcome in colorectal cancer. S. Wangefjord

e14580

Correlation of hypertension and proteinuria with outcomes in elderly bevacizumab (BEV)-treated patients with metastatic colorectal cancer (mCRC): Analysis of the BECOX and BECA studies. A. Salud Salvia

3589

Impact of M1a and M1b staging in patients (pts) with metastatic colorectal cancer. H. F. Kennecke

3590

Prognostic stratification of k-RAS wild type colorectal cancer patients receiving irinotecan-cetuximab treatment: Preliminary results of a prospective study. M. Scartozzi

3591

Reasons for delay in time to initiation of adjuvant chemotherapy (AC) for colon cancer (CC). D. W. Wasserman

e14553

MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. K. P. Raghav

3529

Comorbidity and other predictors of survival in veterans with colorectal cancer (CRC) at different stages. F. Zhong

e14625

UGT1A1*28 polymorphism and vomiting in advanced colorectal cancer. A. E. El Bastawisy

e14678

Association of body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) who received targeted therapies (TT). G. S. Patel

3592

Panitumumab after progression on cetuximab in patients with KRAS wild-TYPE (WT) metastatic colorectal cancer (MCRC): A single institution experience. A. Marino

e14605

Early prediction of therapeutic efficacy of bevacizumab (Bmab) by measuring plasma concentration of βmab-unconjugated free VEGF-α in patients with recurrent or metastatic colorectal cancer (CRC). Y. Cho

e14510

Natural history and outcomes of synchronous and metachronous colorectal cancers (CRC): A population-based analysis. J. Chu

3593

Estrogen and colorectal cancer incidence and mortality in the Women's Health Initiative clinical trial. S. M. Lavasani

3594

Expression of serpin B5 in colorectal cancer: Its relationship with CEA expression. J. Baek

e14606

Cardiac outcomes of raltitrexed in the treatment of colorectal cancer patients with 5-fluorouracil (5-FU) cardiotoxicity. A. Firouzbakht

e14607

A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer. S. Sym

3595

Results of monoclonal antibodies against EGFR-receptors application in patients with metastatic colorectal cancer (mCRC). L. Y. Vladimirova

e14701

Downstaging after preoperative chemoradiation as a prognostic marker for recurrence after curative surgery in locally advanced rectal cancer. J. Lee

e14650

Choice of sequential biologic therapies in metastatic colorectal cancer (mCRC): A cost comparison analysis for wild-type KRAS mCRC patient population in Brazil. R. Weschenfelder

e14679

A French multifactorial prospective study of tumor protein and genetic markers in stage I-III colorectal cancer (CRC): Highlight on molecular characteristics related to mismatch repair (MMR) status. G. Milano

3596

Effect of postoperative chemotherapy (CT) on survival in patients (pts) with resected rectal cancer who received neoadjuvant therapy. C. S. Wu

e14535

Understanding why some people with stage III colon cancer do not receive adjuvant chemotherapy. V. Heong

e14608

Clinical features and outcome of sporadic colorectal carcinoma in young adults: A single center, cross sectional analysis. M. N. Zahir

e14680

Pathway redundancy and feedback loop as drivers of nonresponse in colorectal cancer treatments. H. Kim

e14626

Prognostic significance of tumor stromal and epithelial claudin 2 in metastatic colorectal cancer. A. Mezheyeuski

3597

Aspirin use and survival outcomes in patients (pts) with PIK3CA mutant colorectal cancer (CRC). B. Tran

3598

Serum iron levels potential biomarker in FOLFOX/FOLFIRI with or without molecularly targeted drug therapy. T. Ochiai

e14651

Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status? H. Wong

e14583

Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial. C. Tournigand

3515

Differences in colon cancer incidence rates by latitude. B. K. Shah

e14627

Hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin plus intravenous cetuximab (Cet) (Optiliv) after failure on one versus two or three chemotherapy protocols in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) (European phase II clinical trial NCT00852228). M. Ducreux

3599

A phase II, randomized, double blind comparison of calcium aluminosilicate clay (CASAD) versus placebo (dibasic calcium carbonate) for the prevention of diarrhea in patients (pts) with metastatic colorectal cancer (mCRC) treated with irinotecan (I). B. K. Kee

3600

Prevention of 5-FU-induced health-threatening toxicity by pretherapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach. M. Boisdron-Celle

3601

Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). C. Cremolini

3602

Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial. C. Antoniotti

3603

Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: Patterns of disease progression and outcomes based on extent of disease in the ML18147 study. R. Greil

3604

Chemotherapy first, followed by chemoradiation (CRT) and then surgery, in the management of locally advanced rectal cancer (LARC). A. Cercek

3605

Chronomodulated hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil (5-FU), and oxaliplatin (l-OHP) plus intravenous (iv) cetuximab (Cet) (Chrono-Optiliv) in patients with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after treatment failure (European Phase II trial NCT 00852228). M. Bouchahda

3606

Predictive value of VEGF gene polymorphisms in metastatic colorectal cancer patients treated with a bevacizumab-based chemotherapy. P. Ulivi

e14512

The distribution of chromosomal and microsatellite instability in colorectal cancers related to inflammatory bowel disease. S. Brackmann

3607

hSRBC promoter CpG island hypermethylation as resistant predictive biomarker of oxaliplatin based chemotherapy in metastasic colorectal cancer patients. C. Moutinho

e14609

Efficacy and safety of single agent (SA) or combination (CO) adjuvant chemotherapy (AC) in elderly patients with colon cancer: A Canadian Cancer Institute experience. C. Kim

e14715

Preoperative chemoradiotherapy (QT-RT) with capecitabine and oxaliplatin (CAPOX) in patients with locally advanced rectal cancer. A. Sancho

e14628

Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC). J. Lee

3608^

Association of KRAS mutation with worse recurrence-free survival and site of metastatic progression after resection of hepatic colorectal metastases. N. E. Kemeny

3609

Impact of early tumor shrinkage on clinical outcome in KRAS wild-type colorectal liver-limited metastases treated with cetuximab plus chemotherapy: Lessons from a randomized controlled trial. L. Ye

3610

Prognostic value of incidental betablockers use in metastatic colorectal cancer patients receiving first-line treatment. M. Del Prete

e14610

Gene expression profiles and tumor locations in colorectal cancer (left vs. right vs. rectum). M. K. Maus

3527

Proximal and distal colon tumors as distinct biologic entities with different prognoses. E. Missiaglia

3526

Influence of KRAS mutations on outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy. P. Saletti

e14536

Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). M. Koopman

3502

Are XELOX and FOLFOX equivalent in colorectal cancer? Dose intensity, toxicity, and treatment duration in clinical practice. Y. Gao

e14556

Preoperative chemoradiotherapy (QT-RT) with capecitabine and oxaliplatin (CAPOX) or capecitabine alone (CAP) in patients (PTS) with locally advanced rectal cancer (LARC). I. Marrodan

e14712

Quality of life (QOL) and toxicity among patients in CALGB 80405. M. J. Naughton

3611

Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study. N. Personeni

e14611

Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies. M. Morelli

3512

Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients. S. Kopetz

3612

Management of skin toxicity and cetuximab-based regimen compliance in first-line chemotherapy of metastatic colorectal cancer (mCRC) patients (pts): Results of observer study. C. Pinto

e14557

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). K. S. Oliner

3511

Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). M. Schirripa

3613

Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert’s disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study. T. Lecomte

3614

FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. A. Falcone

3505

Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO). G. Masi

3615

Safety and efficacy of the addition of simvastatin to panitumumab in KRAS mutant metastatic colorectal cancer patients. H. Guchelaar

e14558

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC). A. L. Cohn

3616

Safety and efficacy of the addition of simvastatin to cetuximab in KRAS mutant metastatic colorectal cancer patients. J. M. Baas

e14586

Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer. M. P. Saunders

3521

On-chip drug testing of an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor by kinase activity profiling. R. Ruijtenbeek

e14702

Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408). S. D. Patterson

3617

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial. H. Schmoll

3531

Accent-based nomograms (NGs) to predict time to recurrence (TTR) and overall survival (OS) in stage III colon cancer (CC). L. A. Renfro

3618

Prediction of tumor recurrence by tumor location in stage II and III colon cancer patients through common germ-line variants of genes involved in wnt signaling pathway. W. Zhang

e14714

Comparison of predictors of survival in colon and rectal cancer patients. Y. M. Tang

e14681

Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA. T. Gruenberger

3619^

Immunihistochemical detection of galNAc-T6 to predict survival in patients with colon cancer. L. Ubillos

e14682

Clinical colorectal cancer (CRC) subsets in advanced disease: Patterns of metastatic spread to predict survival. M. T. Bourlon

e14703

Thrombotic events in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab. H. O. Al-Shamsi

e14630

Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). J. Douillard

3620

Multiplatform assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in signet ring cell carcinoma of the gastrointestinal tract. O. B. Alese

e14612

Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer. N. N. Senzer

3621

Methylated miR-124, -137, and -34b/c as predictive biomarkers for ulcerative colitis-associated colorectal neoplasia. Y. Toiyama

e14631

Risk of tumor-related death in stage I-III colon cance based on gender and tumor location. R. D. Ladner

e14538

Capecitabine plus bevacizumab (Cape-Bev) as a maintenance treatment after induction treatment with FOLFIRI plus bevacizumab (FOLFIRI-Bev) in metastatic colorectal cancer (mCRC). A. M. Tatli

e14683

Effect of diet-induced obesity on the efficacy of colon cancer treatment in mice. M. W. Greene

e14632

A central review of resectability of optimally unresectable colorectal liver metastases following neoadjuvant chemotherapy (KSCC0802). M. Takatsuki

e14633

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors. J. Tabernero

3622

Discovering new targeted therapies for BRAF mutant-like colorectal cancers. F. A. San Lucas

3623

Preclinical model for combined effects of metformin and vitamin D3 on colitis-associated colon neoplasia. W. Li

e14634

Association of telomere length with clinical outcomes in patients with colorectal carcinoma. M. A. Baig

e14540

Mortality risk factors and survival of colon cancer patient. R. Shi

e14653

Association between angiotensin-converting enzyme I gene I/d polymorphism and bevacizumab activity in advanced colorectal neoplasm. A. E

e14559

CTLs/regulatory T-cells ratio as a prediction marker of chemotherapy in metastatic colorectal cancer. T. Sasatomi

e14684

Long-course targeted therapy with bevacizumab to predict better survival in patients with advanced colorectal cancer. Y. Deng

e14704

The efficacy and safety of first-line and salvage therapies with bevacizumab combination chemotherapy regimens in metastatic colorectal cancer: A retrospective ASMO experience. R. Yildiz

e14705

Predicting overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with chemotherapy (CT): The British Columbia Cancer Agency (BCCA) mCRC score. L. Chen

3624

Effectiveness of bevacizumab added to gold standard chemotherapy in metastatic colorectal cancer (mCRC): Final results from the Itaca randomized clinical trial. A. Passardi

3517

The study on functions and mechanisms of miR-106b in the metastasis of colorectal cancer. S. Ni

e14685

Preclinical activity of lenalidomide in metastatic colorectal cancer. V. Leuci

e14654

Expression and methylation profiles associated with recurrent mutations in stage II colorectal cancer. L. Pare-Brunet

e14613

Microarray gene expression study of the RESPECT trial for the identification of prognostic and predictive markers. M. Delorenzi

e14561

Phase I dose escalation of the oral histone deacetylase inhibitor (HDACi) resminostat in combination with FOLFIRI in colorectal cancer (CRC) patients: The SHORE trial. H. Schulze-Bergkamen

3625

Is there any difference in overall response rate according to kras mutation in advanced colorectal cancer (aCRC)? J. Rivadeneira Cabana

e14589

Addition of bevacizumab to compensate for the negative influence of attenuated relative dose intensity of cytotoxic agents on the outcome in patients with metastatic colorectal cancer. G. Nakayama

e14614

Third line chemotherapy in metastatic colorectal cancer: A single institution experience. W. F. Carbonel Luyo

e14706

Effect of EGFR inhibition on HER3/PI3K activation by feedback induction of ErbB heterodimers in cetuximab-sensitive colon cancer cells. B. Jacobs

3626

Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase (DPD) deficiency in patients with colorectal cancer. G. Ahmed

3627

TFAP2E methylation status and prognosis of patients with radically resected colorectal cancer. S. Park

3628

Hypermethylation of the KEAP1 gene in colorectal cancer and association with disease progression. E. Maiello

e14655

Benefit-risk evaluation of ziv-aflibercept in combination with irinotecan-fluoropyrimidine-based chemotherapy (FOLFIRI) from the VELOUR trial using multicriteria decision analysis (MCDA). T. Macarulla

e14656

Prognostic biomarkers in a series of stage II colon cancer. C. Santos

3629

Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC. U. R. Mansmann

3630

Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). L. S. Schwartzberg

3631

Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification). S. Marsoni

TPS3648

Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. V. K. Morris

3632

Metformin and biomarkers relevant to neoplasia in nondiabetic patients. M. N. Pollak

e14615

A phase I study of sorafenib with FOLFIRI as first-line therapy for metastatic colorectal cancer (mCRC): Safety and efficacy results. J. A. Maroun

3633

Surgical resection of liver metastases and survival outcomes in real-life for metastatic colorectal cancer (mCRC) patients treated in front-line with cetuximab (CTX): The EREBUS cohort. D. M. Smith

e14514

Genetic variants in EGFR and its ligands to predict response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. A. Sebio

e14541

Neoadjuvant treatment response as a tumor necrosis grade for patients with rectal cancer. B. Shim

e14563

Ultra-deep amplicon sequencing to identify actionable mutations in matched plasma/tumor specimens from 44 patients with colorectal cancer of UICC stage III and IV. P. Pechanska

3634

Uptake of adjuvant chemotherapy (AC) for colon cancer in older and younger patients (pts) in the Irish population. Z. Rehman

e14515

Minor response rate to predict patient survival. B. Zhao

3635

Is adjuvant oxaliplatin (Ox) overutilized in colon cancer (CC): 408 cases from the practices of 102 oncologists. K. Ziel

e14564

Plasma TIMP-1 in patients with metastatic colorectal cancer treated with first-line oxaliplatin-based therapy with or without cetuximab: Results from the Nordic VII study. L. S. Tarpgaard

e14710

Double KRAS and BRAF mutations in colorectal cancer in a single oncologic department series. P. Guglielmini

e14657

Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT). R. Salazar

3530

Cetuximab with irinotecan or oxaliplatin for first-line metastatic colorectal cancer: Effectiveness in the EREBUS cohort compared to pivotal trials. A. Fourrier-Réglat

e14542

Treatment patterns and cost for colorectal cancer by line of therapy and metastasis status. B. S. Seal

e14658

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial. E. Van Cutsem

3636

Clinical characteristics at diagnosis of patients who survive more than 5 years after diagnosis of metastatic colorectal cancer (mCRC). M. Cruz Abrahao

e14590

Clinical impact of first response evaluation (FRE) in metastatic colorectal cancer (mCRC) patients (pts) treated with a cetuximab-based regimen (C-R): Results of a mono-institutional experience. F. L. Rojas Llimpe

e14717

Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. A. Grothey

3637

Association of increased levels of stem cell marker ALDH1 with overall survival in metastatic colon cancer. T. L. Fitzgerald

e14635

Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer. H. Lenz

3514

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. F. Sclafani

e14616

Phase I/II trial of intraperitoneal implantation of agarose-agarose macrobeads (MB) containing mouse renal adenocarcinoma cells (RENCA) in patients (pts) with advanced colorectal cancer (CRC). A. J. Ocean

e14517

The impact of multidisciplinary cancer conferences (MCC) on the treatment of metastatic rectal cancer (MRC) at the Ottawa Hospital Cancer Centre (TOHCC). T. Di Valentin

e14686

Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing wave technology. K. Perez

e14637

Randomized phase III clinical study comparing postoperative UFT/LV,UFT+LV/UFT and UFT+LV+PSK/UFT+PSK as adjuvant therapy for curatively resected stage III colorectal cancer HGCSG-CAD study. T. Shichinohe

3638

Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a determinant of recurrence in stage II colon cancer (CC) patients (pts). D. J. Sargent

3639

Real-world comparative economics of a 12-gene assay for prognosis in stage II colon cancer. T. Yu

3640

Gain of ALK gene copy number to predict lack of response to anti-EGFR treatment in advanced chemorefractory colorectal cancer (CRC) with KRAS/NRAS/BRAF/PI3KCA wild-type status. F. Pietrantonio

3641

Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil, and leucovorin versus oxaliplatin, 5-fluorouracil, and leucovorin versus 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG E3201—An updated survival analysis. H. S. Nimeiri

e14711

Association of a polymorphism in amphiregulin with worse prognosis in metastatic colorectal cancer patients treated with cetuximab. P. M. Wilson

e14543

Optimal treatment strategy in KRAS wild type (wt) metastatic colorectal cancer (mCRC): Cetuximab plus FOLFIRI followed by FOLFOX4 with or without cetuximab-The Capri trial from the Gruppo Oncologico Dell’Italia Meridionale (GOIM). F. Ciardiello

e14565

Bevacizumab before cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin: Analysis of early postoperative complication rate and long term follow-up. C. Eveno

3642

Peripheral immunosuppressive cell levels as predictive marker for the clinical outcome in stage IV colorectal carcinoma. A. Koutoulaki

e14639

Prognostic significance of presence of any mucinous component in curatively resected stage II and III colorectal cancer patients who received adjuvant treatments: Data from a single tertiary center. F. Dane

e14660

Restoration of pro-death function of BAX MSI mutation for selective chemotherapy in colorectal cancer cells. H. Zhang

e14707

Comparison of survival predictors in colorectal cancer (CRC) patients of different races. N. Patel

e14661

Biweekly gemcitabine and capecitabine in heavily pretreated patients with metastatic colorectal cancer (mCRC). M. Solis Hernandez

e14617

Retrospective analysis of 178 patients with stage I rectum cancer. S. Cihan

e14662

TGFBR1 SNP’s are a genetic marker potentially useful for colorectal cancer screening. M. Pauly

e14591

Chemokine receptor CXCR4: What is its role in gastrointestinal cancer? L. Lombardi

e14687

Correlation of bone marrow micrometastases with nodal status in gastrointestinal tumors. S. Nagpal

e14518

Relationship of the emergence of KRAS mutations and resistance to panitumumab in second-line treatment of colorectal cancer (CRC). K. B. Blagoev

e14592

Patterns of care of elderly patients with metastatic colorectal cancer. S. Parakh

e14640

Defective mismatch repair proteins and microsatellite instability in young Mexican patients with colorectal cancer. A. Quintanilla Guzman

e14708

Outcomes of oxaliplatin-based adjuvant chemotherapy in pathologically lymph node positive (ypN+) rectal cancer. A. Al Zahrani

e14664

Pathologic response, KRAS status, and bevacizumab: The Bermuda triangle for outcome prediction after hepatic colorectal cancer metastases (HCRM) resection. G. Fanetti

e14716

The utility of PET scanning in colorectal cancer liver metastases being considered for surgery. J. R. Ismail

e14519

ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation. E. Segelov

TPS3649

Connecting gene expression subtypes of colorectal cancer (CRC) with cell lines and drug resistance. E. Budinska

e14544

Association of mesenchymal phenotype in circulating tumor cells with poor prognosis in metastatic colorectal cancer. A. Dasari

e14567

Nodal status after preoperative chemoradiotherapy (CRT) in locally advanced rectal cancer: Prognostic evaluation of number of resected lymph nodes (LNs), metastatic resected LNs, and LN ratio in the National Cancer Institute of Brazil. F. M. Vieira

e14568

Maintenance with the TLR-9 agonist MGN1703 versus placebo in patients with advanced colorectal carcincoma (mCRC): A randomized phase II trial (IMPACT). J. Riera-Knorrenschild

3643

Oxaliplatin given by hepatic arterial infusion (HAI) or systemic (SYS) with capecitabine in patients (pts) with unresectable liverlimited metastasis (Ur-LLM) from colorectal cancer (CRC). B. V. Jensen

e14593

Use of surgery and chemoradiation in stage II and III rectal cancer: A retrospective comparison of treatment modalities in major insurance types using the NCDB. M. Warlaumont

e14641

Visceral fat as a predictive marker of response to bevacizumab-based treatment in metastatic colorectal cancer. Y. Miyamoto

e14665

Locally advanced rectal cancer: The value of magnetic resonance imaging as a predictive tool. L. C. Connell

e14666

Association of aspirin use with improved 5-year survival in colorectal cancer patients with PIK3CA mutation. N. Kothari

3644

Diabetes as a predictor of colon cancer prognosis: A single institution based retrospective data analysis. N. Ammannagari

e14709

Association of the polymorphisms of the tandem repeat sequence in the thymidylate synthase gene with tumor stage in colon cancer. S. Aguiar

e14688

An overview of clinical and economic outcomes of U.S. veteran colorectal cancer patients. O. Baser

e14689

Incidence and impact of K-ras mutation in colorectal cancer (CRC) in a minority population. D. Dietz

e14690

Effect of microRNA-202-3p on cell proliferation and targeting of ADP-ribosylation factor-like 5A in human colorectal carcinoma. Q. WANG

e14667

Safety and efficacy of 90y resin microspheres in elderly (≥70 years) compared to younger patients with colorectal liver metastases (mCRC). A. S. Kennedy

e14545

Impact of the Recurrence Score (RS) result and mismatch repair status (MMR) on agreement between oncologists (MDs) for stage II colon cancer (CC) recurrence risk (RR) assessment: A novel clinical utility endpoint for prognostic markers. R. K. Kelley

e14569

Leucovorin shortage: Impact on leucovorin/levoleucovorin usage and tx choices in colon cancer patients treated in the United States. A. Katler

e14668

Role of clinical variables for predicting pathologic response to neoadjuvant chemoradiation in locally advanced rectal cancer. P. M. Taglietti

e14691

Choice of therapy and time to first treatment for patients with colon cancer: A National Cancer Database analysis. D. C. Olson

e14642

Evolving disparities in colorectal cancer control in Texas in the first decade of twenty-first century and implications for cancer control. D. Vugrin

e14643

Primary tumor resection to improve survival in patients with metastatic colorectal cancer in the post-2000 era: A California Cancer Registry analysis. A. M. Rodriguez Fahrni

e14570